C(OC(N[C@H]1CC[C@H](C(O)=O)CC1)=O)C1C=CC=CC=1.[Br:21][C:22]1[N:23]=[C:24]([C@H:32]2[CH2:37][CH2:36][C@H:35]([NH2:38])[CH2:34][CH2:33]2)[N:25]2[CH:30]=[CH:29][N:28]=[C:27]([CH3:31])[C:26]=12.C(=O)([O-])[O-].[K+].[K+].Br[CH2:46][CH:47]([F:49])[F:48]>CN(C)C=O>[Br:21][C:22]1[N:23]=[C:24]([C@H:32]2[CH2:37][CH2:36][C@H:35]([NH:38][CH2:46][CH:47]([F:49])[F:48])[CH2:34][CH2:33]2)[N:25]2[CH:30]=[CH:29][N:28]=[C:27]([CH3:31])[C:26]=12Using the procedures described in example 17 (trans)-4-(benzyloxycarbonylamino)cyclohexanecarboxylic acid was used to prepare (trans)-4-(1-bromo-8-methylimidazo[1,5-a]pyrazin-3-yl)cyclohexanamine. The latter compound (0.217 mmol, 67.1 mg) was dissolved in N,N-dimethylformamide, potassium carbonate (0.651 mmol, 90 mg) was added followed by 2-bromo-1,1-difluoroethane (0.217 mmol, 17.47 μl, 31.5 mg) and the reaction mixture was stirred in the micro wave at 60° C. After one hour another amount of 2-bromo-1,1-difluoroethane (0.217 mmol, 17.47 μl, 31.5 mg) was added and the reaction mixture was stirred in the micro wave at 60° C. for another hour. The reaction mixture was filtered, the filter was rinsed with acetonitrile and the filtrate was concentrated. The residue was purified by column chromatography (silica gel, gradient dichloromethane/methanol 10/0 to 9/1) to give (trans)-4-(1-bromo-8-methylimidazo[1,5-a]pyrazin-3-yl)-N-(2,2-difluoroethyl)cyclohexanamine (39.8 mg).